title: High affinity phenylglycinol-based NK1 receptor antagonists.
abstract: Heterocyclic replacements for the carboxamido group of the previously disclosed phenylglycinol-based human NK1 (hNK1) receptor antagonists have been investigated, ultimately leading to acyclic compounds with sub-nanomolar affinity for the hNK1 receptor.
authors.affiliation: Department of Medicinal Chemistry, Merck Sharp and Dohme Research Laboratories, Harlow, Essex, U.K. andrew_owens@merck.com
authors.forename: A P
authors.initials: AP
authors.lastname: Owens
authors.forename: T
authors.initials: T
authors.lastname: Harrison
authors.forename: J D
authors.initials: JD
authors.lastname: Moseley
authors.forename: C J
authors.initials: CJ
authors.lastname: Swain
authors.forename: S
authors.initials: S
authors.lastname: Sadowski
authors.forename: M A
authors.initials: MA
authors.lastname: Cascieri
mesh_terms: D004983:Ethanolamines; D005998:Glycine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D015394:Molecular Structure; D064729:Neurokinin-1 Receptor Antagonists; D013329:Structure-Activity Relationship
chemical_list: D004983:Ethanolamines; D064729:Neurokinin-1 Receptor Antagonists; C005332:N-phenylethanolamine; D005998:Glycine